Sectors
OLMA
Olema Pharmaceuticals, Inc.
9.82
2 x 7.04
2 x 12.51
bid
ask
-
0.08
0.81%
2 @ 07:30 PM
9.82 +0.00 (0.00%)
| Ytd | -60.72% | |
| 1y | 15.39% |
9.75
day range
9.93
7.77
52 week range
35.83
| Open | 9.88 | Prev Close | 9.90 | Low | 9.75 | High | 9.93 | Mkt Cap | 859.23M |
| Vol | 3.06M | Avg Vol | 1.24M | EPS | -2.12 | P/E | N/A | Forward P/E | -4.86 |
| Beta | 2.01 | Short Ratio | 7.94 | Inst. Own | 118.48% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 11.07 | 200-d Avg | 17.19 | 1yr Est | 40.70 |
| Income Statement | |||
| Operating Expenses | 67.18M | ||
| Research and Development Expense | 57.79M | ||
| Selling, General and Administrative Expense | 9.39M | ||
| Operating Income | -67.18M | ||
| Net Income | -63.20M | ||
| Net Income Common Stock | -63.20M | ||
| Net Income Common Stock (USD) | -63.20M | ||
| Consolidated Income | -63.20M | ||
| Earnings per Basic Share | -0.61 | ||
| Earnings per Basic Share (USD) | -0.61 | ||
| Earnings per Diluted Share | -0.61 | ||
| Earning Before Interest & Taxes (EBIT) | -63.20M | ||
| Earning Before Interest & Taxes (USD) | -63.20M | ||
| Weighted Average Shares | 104.45M | ||
| Weighted Average Shares Diluted | 104.45M | ||
| Balance Sheet | |||
| Cash and Equivalents | 48.60M | ||
| Cash and Equivalents (USD) | 48.60M | ||
| Investments | 412.47M | ||
| Investments Current | 412.47M | ||
| Current Assets | 469.88M | ||
| Property, Plant & Equipment Net | 638.00K | ||
| Total Assets | 486.58M | ||
| Debt Current | 660.00K | ||
| Total Debt | 3.66M | ||
| Current Liabilities | 53.01M | ||
| Debt Non-Current | 3.00M | ||
| Total Liabilities | 56.01M | ||
| Accumulated Retained Earnings (Deficit) | -713.85M | ||
| Accumulated Other Comprehensive Income | -947.00K | ||
| Shareholders Equity | 430.56M | ||
| Shareholders Equity (USD) | 430.56M | ||
| Assets Non-Current | 16.70M | ||
| Total Debt (USD) | 3.66M | ||
| Liabilities Non-Current | 3.00M | ||
| Trade and Non-Trade Payables | 1.67M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 402.00K | ||
| Net Cash Flow from Financing | 1.11M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -3.95M | ||
| Capital Expenditure | -221.00K | ||
| Issuance (Purchase) of Equity Shares | -3.54M | ||
| Net Cash Flow from Investing | 40.84M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 41.06M | ||
| Net Cash Flow from Operations | -45.90M | ||
| Share Based Compensation | 12.90M | ||